KSQ-4279

N/A

Report date: 2024/11/08 16:25:22
NME

Base Information

Drug NameKSQ-4279
Drug Alias NameKSQ-4279RO7623066RO-7623066RG6614RG-6614
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA damage stimulantsCell cycle inhibitorsUbiquitin carboxyl-terminal hydrolase 1 inhibitors +[4] 
TargetsUbiquitin carboxyl-terminal hydrolase 1
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKSQ Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdKSQ Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A